Sheila K. Gujrathi
Member of Advisory BoardDr. Sheila K. Gujrathi, M.D., has been Executive Chair of the Board of Processa Pharmaceuticals, Inc. since October 28, 2026. Dr. Gujrathi serves as Director of Processa Pharmaceuticals, Inc. from July 28, 2026. She is Chief Strategy Officer & Director of Bolt Biotherapeutics, Inc. from October 23, 2026. Dr. Gujrathi is Co-Founder and Director of Prana Therapies, Inc. and served as CEO until October 23, 2026. Dr. Gujrathi is a seasoned biotech entrepreneur, physician executive, translational scientist and drug developer. Dr. Gujrathi has served as an Independent Director of BlossomHill Therapeutics, Inc. from May 15, 2026 and also serves as its Lead Independent Director since May 15, 2026. Dr. Gujrathi is founder and Chief Executive Officer of Prana Therapies since March 2023, as founder and Executive Chair of the board of directors of Lila Biologics, Inc., a privately held biopharmaceutical company, since March 2023, as founder and Executive Chair of the board of directors of Vidya Therapeutics, Inc., a privately held biotechnology company, since March 2023 until the Acquisition, as Executive Chair of the board of directors of Ventyx Biosciences, Inc., a publicly held biopharmaceutical company, since May 2021 until March 4, 2026 and as Executive Chair of the board of directors of Generian Pharmaceuticals, Inc., a privately held biotechnology company, since May 2023. Dr. Gujrathi has served as a member of the board of directors of Janux Therapeutics, Inc., a publicly held biopharmaceutical company, since March 2021 until June 11, 2026. Dr. Gujrathi served as Chair of the Board of ImmPACT Bio USA Inc., a privately held biotechnology company, since January 2022 until its acquisition by Lyell Immunopharma, Inc. in October 2024. Dr. Gujrathi is Member of Scientific Advisory Board of Soley Therapeutics, Inc. since December 2024. Dr. Gujrathi is a Senior Advisor at Qiming Venture Partners USA since January 2023. Dr. Gujrathi served as Venture Partner at OrbiMed Advisors LLC since joining the firm in November 2021. Dr. Gujrathi previously served as Chair of the board of directors of ADARx Pharmaceuticals, Inc., a privately held biopharmaceutical company, from June 2020 to January 2025. Dr. Gujrathi served as Member of Advisory Board at Aardvark Therapeutics, Inc. Dr. Gujrathi served as Chairman of the Board at Turning Point Therapeutics, Inc. (acquired by Bristol-Myers Squibb Company in August 2022), a then-publicly held biopharmaceutical company, since April 2019 until March 2021 and its Director since November 2017 until March 2021. Dr. Gujrathi previously served as a member of the board of directors of Five Prime Therapeutics, Inc. (acquired by Amgen, Inc. in April 2021) since December 2, 2015 until June 07, 2019 and as a member of the board of directors of Ambrx, Inc., a then-publicly held biopharmaceutical company, since February 24, 2014 until its acquisition by Johnson & Johnson in June 2015. Dr. Gujrathi is a Co-Founder of Gossamer Bio, Inc., a publicly held biopharmaceutical company and served as its President and Chief Executive Officer from July 2018 to November 2020 and as its President and Chief Operating Officer from October 2015 to June 2018 and as a member of its board of directors from October 2015 to November 2020. Dr. Gujrathi has been Strategic Advisor at TP Therapeutics, Inc. since December 2017. Dr. Gujrathi has been a Director of TP Therapeutics, Inc. since December 2017. Dr. Gujrathi is a Director of Gale Therapeutics, Inc. Dr. Gujrathi serves as a Member of Advisory Board of BioXcel Therapeutics, Inc. Previously, Dr. Gujrathi was the Chief Medical Officer of Receptos, Inc., a then-publicly held biopharmaceutical company, a position she held from June 2011 until its acquisition by Celgene Corporation in August 2015. Dr. Gujrathi led expansion of development activities for both the S1P1 agonist portfolio and additional assets in the immunology therapeutic area at Receptos, Inc. Previously, Dr. Gujrathi worked at Bristol-Myers Squibb Company, where she served as Vice President of the Global Clinical Research Group in Immunology from August 2008 to June 2011. Dr. Gujrathi was responsible for late-stage clinical development for Orencia(R), Nulojix(R) and other clinical immunology assets being developed in rheumatoid arthritis (RA), solid organ transplant, systemic lupus erythematosus, juvenile idiopathic arthritis (JIA) and inflammatory bowel disease. Dr. Gujrathi was instrumental in preparing several regulatory submissions in the US, EU and other countries for Orencia(R) IV and SC sBLA applications in RA and JIA, as well as for Nulojix(R) in kidney transplant recipients. In addition, she provided strategic direction and leadership for the Immunoscience franchise at BMS, including external business development opportunities, where she was involved in acquisitions of several immunology compounds both in the discovery and clinical stages of development. Prior, Dr. Gujrathi worked at Genentech, Inc., where she held roles of increasing responsibility in the Immunology, Tissue Growth and Repair clinical development group from Oct 2002 to July 2008 and served as the Avastin franchise team leader. From 1999 until 2002, Dr. Gujrathi was a management consultant at McKinsey & Company in the healthcare practice, where she provided strategic advice on a variety of projects in the healthcare and pharmaceutical industry. Dr. Gujrathi has extensive development, clinical and executive management experience. Dr. Gujrathi has wealth of knowledge and clinical development experience in immunology to in-license additional programs for preclinical and clinical development pipeline. Dr. Gujrathi was named amongst "50 Female Entrepreneurs Everyone Should Know" in March 2019. Dr. Gujrathi received her Bachelor of Science in Biomedical Engineering and M.D. from Northwestern University in the accelerated Honors Program in Medical Education. Dr. Gujrathi completed her internal medicine internship and residency at Brigham and Women's Hospital, Harvard Medical School and is board certified in internal medicine. Dr. Gujrathi received additional fellowship training in Allergy/Immunology at UCSF and Stanford University in their Allergy and Immunology Fellowship Program.
Positions
- Company NameBioXcel Therapeutics, Inc.Stock CodeBTAIQPositionMember of Advisory BoardColleagues
- VDVimal D. MehtaFounder & Director
- PRPeter R. MuellerIndependent Chairman & Lead Director
- SSSamir SaleemPresident, Secretary, Principal Executive Officer & Chief Restructuring Officer
- MHMark H. PavaoActing Chief Commercial Officer
- MMMatt MandelVice President of Clinical Development
- SLSandeep LaumasIndependent Director
- SMSteven M. PaulMember of Advisory Board
- Company NameProcessa Pharmaceuticals, Inc.Stock CodePCSAPositionExecutive Chair of the BoardColleagues
- GKGeorge K. NgCEO & Director
- SKSheila K. GujrathiExecutive Chair of the Board
- RLRussell L. SkibstedChief Financial Officer
- DYDavid YoungCo-Founder, President of Research and Development & Director
- PLPatrick LinCo-Founder, Chief Business & Strategy Officer
- JWJustin W. YorkeIndependent Director
- GLGeraldine Liu PannuIndependent Director
- Company NameBlossomHill Therapeutics, Inc.Stock CodeBLSMPositionLead Independent DirectorColleagues
- YLYishan LiCo-Founder & Executive Chairman
- JJJingrong Jean CuiScientific Founder, President, CEO & Director
- JAJason A. KeyesCFO & Executive VP
- GOGeoff OxnardChief Medical Officer & Executive VP
- VLVincent LiptakGeneral Counsel & Executive VP
- BCBihua ChenIndependent Director
- SKSheila K. GujrathiLead Independent Director
- JPJohn P. SchmidIndependent Director
- Company NameBolt Biotherapeutics, Inc.Stock CodeBOLTPositionCo-Founder & Director
